Ness Ziona, Israel, June 24, 2015 – BiondVax Pharmaceuticals Ltd. (TASE: BVXV, Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters. The underwriters purchased 110,000 additional American Depositary Shares (ADSs) at a public offering price of $5.00 per ADS, whereby each ADS represents 40 of BiondVax’s ordinary shares, bringing aggregategross proceeds from the offering to $10,120,380, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BiondVax. The closing with respect to these over-allotment option shares was consummated on June 24, 2015.
Aegis Capital Corp. acted as the sole book-running manager for the offering.
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission on May 11, 2015.
A prospectus relating to the offering has been filed with the SEC and is available on the SEC’s web site at http://www.sec.gov. Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: firstname.lastname@example.org, or from the above-mentioned SEC website.